Stay updated on MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial

Sign up to get notified when there's something new on the MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0, with two locations now included, replacing the previous version v2.9.7.
    Difference
    0.3%
    Check dated 2024-07-23T14:31:39.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:22:27.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T13:44:28.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T09:56:41.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T08:42:48.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Genetic and Rare Diseases Information Center resources: Transitional Cell Carcinoma Drug Information available for: Paclitaxel Albumins Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Pembrolizumab + nab-paclitaxel pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously Drug : Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8. Primary Outcome Measures Outcome Measure Measure Description Time Frame Progression-free-survival Increment of median PFS from 3 months to 5 months, with 10% of statistical significance Through study completion, average 4 months Secondary Outcome Measures Outcome Measure Measure Description Time Frame Incidence of all-grade and grade 3-4 side effects number of patients with adverse events, frequency and type of adverse events 9 weeks Objective response-rate (ORR) to RECIST v1.1 criteria Rate of complete response + partial response 9 weeks Overall survival overall survival Through study completion, average 6 months Additional Relevant MeSH Terms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Carcinoma Carcinoma, Transitional Cell Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Paclitaxel Pembrolizumab Albumin-Bound Paclitaxel Plan to Share Individual Participant Data (IPD)? Undecided Studies a U.S. FDA-Regulated Drug Product No Studies a U.S. FDA-Regulated Device Product No Product Manufactured in and Exported from the U.S. No Helpful Links Provided by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study Revision: v2.9.1'
    Difference
    13%
    Check dated 2024-06-25T08:24:12.000Z thumbnail image

Stay in the know with updates to MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MND-2119 Long-Term Safety/Efficacy in Hypertriglyceridemia Clinical Trial page.